All In MedTech

Device Trial Radar · NCT04473963

FLOW-AF: A Study to Evaluate Electrographic Flow™ (EGF) Mapping Technology

A Randomized Controlled Study to Evaluate the Reliability of Electrographic Flow™ (EGF) Mapping Algorithm Technology to Identify Sources of Atrial Fibrillation and Guide Ablation Therapy in Patients With Persistent Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

85

Actual

Start

Sep 27, 2019

Primary completion

Sep 27, 2021

Study completion Sep 27, 2021

Sponsor

Lead sponsor
CortexNot on our public-company list
Sponsor type
Industry
Collaborators
Ablacon, Inc.
First posted
Jul 16, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate Electrographic Flow™ (EGF) mapping algorithm technology (Ablamap® Software).

Conditions

  • Atrial Fibrillation, Persistent

Interventions

  • Electrographic Flow™ guided ablationDevice

    In addition to standard pulmonary vein isolation (PVI) or PVI touch-up, subjects receive targeted radiofrequency source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF). EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 26.5%) are considered significant and targeted for ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Acute Procedure SuccessTime frame: During the Procedure
  2. Number of Participants With Serious Adverse Events Related to the Procedure Through 7 DaysTime frame: 7 days

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Nemocnice Na Homolce Hospital

    Prague, Czech Republic, Czechia

  • University Heart and Vascular Center Hamburg

    Hamburg, Germany

  • Practice Clinic Heart And Vessels

    Dresden, Saxony Land, Germany

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.